The King of Ozempic Is Scared as Hell
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
Novo Nordisk Defends Next-Gen Obesity Drug CagriSema, Gives Details of New Trial
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...
devdiscourse1d
Challenges and Confidence: Novo Nordisk's CagriSema Trial and Market Response
Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...
devdiscourse1d
Novo Nordisk's Bold Bet: CagriSema's Next Chapter in Obesity Treatment
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
Reuters8d
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
Reuters8d
Novo Nordisk says it has not yet posted details about new CagriSema trial
Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...
Morningstar6d
Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
CASE DETAILS: According to the complaint ... "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight ...
Yahoo Finance7d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...
Business Insider5d
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
CASE DETAILS: According to the complaint ... "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight ...
Business Insider9d
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
CASE DETAILS: According to the complaint ... "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight ...
Mena FN8d
NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors Of A Class Action Lawsuit And Upcoming Deadline
The trial showed that patients treated with CagriSema exhibited weight loss of ... with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March ...